Associated tags: Fertilizer, Research, Heparin, Hospital, COVID-19, Government, Ningxia, Public health, Health, Sale, Taylor & Francis, Enoxolone, Coronavirus, Pharmaceutical industry
Fertilizer,
Research,
Heparin,
Hospital,
Private Securities Litigation Reform Act,
COVID-19,
SEC,
Government,
Review,
Ningxia,
Marketing,
Company,
Phrase,
CEO,
Public health,
Health,
Nasdaq,
Sale,
Taylor & Francis,
Enoxolone,
Coronavirus,
Pharmaceutical industry The Company donated RMB2 million worth of drugs to the affected areas in Hubei back in the early days of the COVID-19 outbreak.
Key Points:
- The Company donated RMB2 million worth of drugs to the affected areas in Hubei back in the early days of the COVID-19 outbreak.
- Mr. Zhanchang Xin, Chairman and CEO of the Company, commented, "The global COVID-19 pandemic is still ongoing and spreading rapidly.
- As a pharmaceutical company, we take the responsibility to help fight the local epidemic and protect the public health."
- Qilian International Holding Group Limited, headquartered inGansu, China, is a pharmaceutical and chemical products manufacturer inChina.
Retrieved on:
Thursday, September 16, 2021
People,
Company,
Chief executive officer,
Research,
Industry,
Phrase,
Keita Integrated Development Project,
Technology,
Degenerative disease,
United States,
Breeding,
Sichuan,
Private Securities Litigation Reform Act,
Review,
Project,
Industrialisation,
Fertilizer,
Anticoagulant,
Sale,
SEC,
Agreement,
Nasdaq,
Income,
Death,
Marketing,
Conference,
GLOBE,
Fine chemical,
Pharmaceutical industry Pursuant to the Agreement, the Companys new pig by-product processing facility (the Project) will be located in Tongnan High-tech Zone.
Key Points:
- Pursuant to the Agreement, the Companys new pig by-product processing facility (the Project) will be located in Tongnan High-tech Zone.
- Since 2020, the Company's heparin sodium industrialization development plan has received high attention from local and neighboring local governments.
- In March 2021, the Project was listed as one of key investment projects by Chongqing Tongnan High-Tech Zone.
- Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China.
The Project is expected to receive preferential policies from the government at the national, municipal and local levels.
Key Points:
- The Project is expected to receive preferential policies from the government at the national, municipal and local levels.
- Mr. Zhanchang Xin, Chairman and CEO of the Company, commented, We are very pleased to work with CJT on the Project.
- As a key area for pig breeding and pork production in China, Chongqing has sufficient raw materials for the production of heparin sodium preparations.
- Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China.
In addition, Gan Di Xin\xc2\xae has unparalleled taste and efficacy compared with traditional antitussive and expectorant drugs, making it an upgraded product among similar drugs.\nMr.
Key Points:
- In addition, Gan Di Xin\xc2\xae has unparalleled taste and efficacy compared with traditional antitussive and expectorant drugs, making it an upgraded product among similar drugs.\nMr.
- Zhanchang Xin, Chairman and CEO of the Company, commented, \xe2\x80\x9cWe are very pleased to cooperate with Kangzhiyuan.
- Previously, we marketed Gan Di Xin\xc2\xae mainly through third-party platforms in towns such as healthcare centers, individual clinics, and pharmacies.
- We believe the national marketing channels and sales network of Kangzhiyuan will greatly assist us in achieving record sales for the compound licorice lozenges product.
In addition, 10 out of these 16 products have been included in the latest version of the National Essential Medicines List in China.\nNational Reimbursement Drug List is the list of products eligible for reimbursement in China, as maintained by the National Healthcare Commission of China.
Key Points:
- In addition, 10 out of these 16 products have been included in the latest version of the National Essential Medicines List in China.\nNational Reimbursement Drug List is the list of products eligible for reimbursement in China, as maintained by the National Healthcare Commission of China.
- The National Essential Medicines List is one of the core contents of the essential medicines system.
- Zhanchang Xin, Chairman and CEO of the Company, commented, \xe2\x80\x9cWe are excited to have 16 of our products included in the National Reimbursement Drugs List and 10 out of these 16 products also included in the National Essential Medicines List in China.
- This means that our products may benefit from being included on such list and their market share grow consequently.\xe2\x80\x9d\nQilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China.
Retrieved on:
Thursday, February 18, 2021
Jiuquan, China, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the Company), a China-based pharmaceutical and chemical products manufacturer, today announced that its Chairman and Chief Executive Officer, Mr. Zhanchang Xin, received the Outstanding Entrepreneur Award from the Economic and Technological Development Zone of Jiuquan City in February 2021.
Key Points:
- Jiuquan, China, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the Company), a China-based pharmaceutical and chemical products manufacturer, today announced that its Chairman and Chief Executive Officer, Mr. Zhanchang Xin, received the Outstanding Entrepreneur Award from the Economic and Technological Development Zone of Jiuquan City in February 2021.
- The Outstanding Entrepreneur Award is presented to chief executive officers of businesses in a wide range of industries and sectors with leadership skills, innovation, and entrepreneurial vision.
- Mr. Xin commented: I am honored to receive the Outstanding Entrepreneur Award and I am proud of all the work our team has done over the years to make it happen.
- Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer.
Retrieved on:
Thursday, February 11, 2021
The Company expects to triple its organic fertilizer production capacity upon completion of its first phase expansion.
Key Points:
- The Company expects to triple its organic fertilizer production capacity upon completion of its first phase expansion.
- With a tripled production capacity, the Company has won bids for government organic fertilizer projects in Tibet, Gansu and Qinghai.
- As each mu of arable land consumes 150-200 kilograms of organic fertilizer, the organic fertilizer market in China has tremendous potential.
- Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China.
Retrieved on:
Tuesday, January 19, 2021
Gross proceeds of the Company's initial public offering, including the exercise of the overallotment, totaled $28.75 million, before deducting underwriting discounts and other related expenses.
Key Points:
- Gross proceeds of the Company's initial public offering, including the exercise of the overallotment, totaled $28.75 million, before deducting underwriting discounts and other related expenses.
- The ordinary shares began trading on the Nasdaq Global Market on January 12, 2021 under the ticker symbol QLI.
- Univest Securities, LLC acted as the representative of the underwriters and lead book-running manager for the Offering.
- Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China.
